AGL 40.15 Increased By ▲ 0.15 (0.38%)
AIRLINK 130.70 Increased By ▲ 1.17 (0.9%)
BOP 6.85 Increased By ▲ 0.17 (2.54%)
CNERGY 4.63 No Change ▼ 0.00 (0%)
DCL 9.00 Increased By ▲ 0.06 (0.67%)
DFML 43.51 Increased By ▲ 1.82 (4.37%)
DGKC 84.19 Increased By ▲ 0.42 (0.5%)
FCCL 33.00 Increased By ▲ 0.23 (0.7%)
FFBL 78.65 Increased By ▲ 3.18 (4.21%)
FFL 11.80 Increased By ▲ 0.33 (2.88%)
HUBC 110.80 Increased By ▲ 0.25 (0.23%)
HUMNL 14.63 Increased By ▲ 0.07 (0.48%)
KEL 5.68 Increased By ▲ 0.29 (5.38%)
KOSM 8.32 Decreased By ▼ -0.08 (-0.95%)
MLCF 39.81 Increased By ▲ 0.02 (0.05%)
NBP 61.00 Increased By ▲ 0.71 (1.18%)
OGDC 199.90 Increased By ▲ 0.24 (0.12%)
PAEL 26.80 Increased By ▲ 0.15 (0.56%)
PIBTL 7.82 Increased By ▲ 0.16 (2.09%)
PPL 160.49 Increased By ▲ 2.57 (1.63%)
PRL 26.85 Increased By ▲ 0.12 (0.45%)
PTC 18.80 Increased By ▲ 0.34 (1.84%)
SEARL 83.73 Increased By ▲ 1.29 (1.56%)
TELE 8.22 Decreased By ▼ -0.09 (-1.08%)
TOMCL 34.45 Decreased By ▼ -0.06 (-0.17%)
TPLP 9.12 Increased By ▲ 0.06 (0.66%)
TREET 17.05 Decreased By ▼ -0.42 (-2.4%)
TRG 59.83 Decreased By ▼ -1.49 (-2.43%)
UNITY 27.81 Increased By ▲ 0.38 (1.39%)
WTL 1.43 Increased By ▲ 0.05 (3.62%)
BR100 10,556 Increased By 149.1 (1.43%)
BR30 32,022 Increased By 309 (0.97%)
KSE100 98,490 Increased By 1161.1 (1.19%)
KSE30 30,645 Increased By 452.8 (1.5%)
World

Two AstraZeneca COVID shots 85-90pc effective: UK real-world analysis

  • Estimated 89% effectiveness against symptomatic disease.
  • Analysis is first to study two AZ doses in real world setting.
  • Pfizer shot effectiveness drops off 10 weeks after first dose.
Published May 20, 2021

LONDON: Two doses of the Oxford/AstraZeneca COVID-19 vaccine are around 85% to 90% effective against symptomatic disease, Public Health England (PHE) said on Thursday, citing an analysis of real-world data from the rollout of the shot.

Britain has suffered one of the worst death tolls globally from the pandemic, but has also had one of the fastest vaccine rollouts, generating a lot of data about the use of the shots in real world settings.

In a weekly surveillance report, Public Health England said the estimated effectiveness of the AstraZeneca vaccine, invented at the University of Oxford, was 89% compared to unvaccinated people.

That compares to 90% estimated effectiveness against symptomatic disease for the Pfizer/BioNTech vaccine.

"This new data highlights the incredible impact that both doses of the vaccine can have, with a second dose of the Oxford/AstraZeneca vaccine providing up to 90% protection," vaccines minister Nadhim Zahawi said.

PHE said the analysis was the first of its kind on the effectiveness of two doses of AstraZeneca in a real-world setting but was not yet published in a journal, adding more data would boost its confidence in the finding.

Britain has been rolling out the shots manufactured by Pfizer and AstraZeneca since December and January respectively, and in April also started rolling out Moderna's vaccine.

PHE said there was a "small reduction in vaccine effectiveness" from 10 weeks after the first dose of the Pfizer shot before the second shot is given.

Britain extended the gap between doses to 12 weeks, though Pfizer warned there was a lack of evidence of its efficacy outside the three-week gap used in trials.

Last week, Britain cut the gap between doses down to 8 weeks for the over 50s, aiming to give maximum protection to more vulnerable people in light of concern about the B.1.617.2 variant first found in India.

Comments

Comments are closed.